Arrowhead Pharmaceuticals
ARWR
Performance
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and delivering RNA interference (RNAi)–based therapies across multiple disease areas, including cardiometabolic and inflammatory pulmonary diseases. Its TRiM platform targets genes to silence disease-causing pathways, with programs addressing conditions such as severe hypertriglyceridemia, dyslipidemia, and various cardiovascular and lung diseases. The company operates globally with research and development activities and clinical trials in several countries, including the United States, Australia, Canada, and Europe.
Recent News
Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial
Arrowhead Pharmaceuticals Receives the CHMP’s Positive Opinion for Redemplo (Plozasiran) to Treat Familial Chylomicronemia Syndrome (FCS)
Arrowhead siRNA Data in Obesity Mark POC for Adipose Delivery
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
S&P 500 Closes at a New Record to Usher in May as Oil Prices Cool and Apple Rises: Live Updates
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
2025 Novel Large Molecule FDA Drug Approvals
Parkinson’s Awareness Month and World Parkinson’s Day 2026: Advocacy and Therapeutic Progress
Atrium Therapeutics Inc (RNA) Q1 2026 Earnings Call Transcript
Regulatory Round-Up: Novartis, Sanofi and Arrowhead Secure CHMP Blessings
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (Plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?